Matt Hewitt
Stock Analyst at Craig-Hallum
(4.14)
# 317
Out of 4,829 analysts
42
Total ratings
60%
Success rate
10.51%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.01 | +99.67% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $3.47 | +72.91% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $23.89 | +33.95% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $27.46 | +133.07% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $106.38 | +31.60% | 3 | Jul 9, 2024 | |
| SLP Simulations Plus | Reiterates: Buy | $56 | $30.82 | +81.70% | 7 | Jul 3, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $2.19 | +356.62% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $24.17 | +24.12% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $2.27 | +208.37% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $133.72 | +49.57% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.43 | +599.30% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $7.35 | +308.16% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.17 | +34,088.03% | 1 | Jan 4, 2022 |
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.01
Upside: +99.67%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $3.47
Upside: +72.91%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $23.89
Upside: +33.95%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $27.46
Upside: +133.07%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $106.38
Upside: +31.60%
Simulations Plus
Jul 3, 2024
Reiterates: Buy
Price Target: $56
Current: $30.82
Upside: +81.70%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $2.19
Upside: +356.62%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $24.17
Upside: +24.12%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $2.27
Upside: +208.37%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $133.72
Upside: +49.57%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.43
Upside: +599.30%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $7.35
Upside: +308.16%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $1.17
Upside: +34,088.03%